Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 14/20 | 0.55 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.52 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288663 | 0.93 | GABRA5 (0.54) | GABRA5ITGA5GABRA1POLBMDM2 | |
| SCHEMBL287977 | 0.91 | GABRA5 (0.55) | GABRA5ITGA5GABRA1POLBMDM2 | |
| SCHEMBL289211 | 0.90 | GABRA5 (0.57) | GABRA5ITGA5GABRA1POLBMDM2 | |
| SCHEMBL287943 | 0.89 | GABRA5 (0.71) | GABRA5ITGA5GABRA1 | |
| SCHEMBL288662 | 0.89 | GABRA5 (0.68) | GABRA5ITGA5GABRA1 | |
| SCHEMBL288229 | 0.88 | GABRA5 (0.70) | GABRA5ITGA5GABRA1 | |
| SCHEMBL288200 | 0.87 | GABRA5 (0.66) | GABRA5ITGA5POLBMDM2SMN1; SMN2 | |
| SCHEMBL288742 | 0.87 | GABRA5 (0.65) | GABRA5ITGA5POLBMDM2SMN1; SMN2 | |
| SCHEMBL287698 | 0.86 | GABRA5 (0.69) | GABRA5ITGA5GABRA1 | |
| SCHEMBL288080 | 0.86 | GABRA5 (0.55) | GABRA5ITGA5GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427456-B1 | ISOXAZOLE-PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-02-05 | — | — | EP | claimed |
| EP-2427456-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-03-14 | — | — | EP | claimed |
| US-20100286132-A1 | PYRIDINES | ROCHE PALO ALTO LLC | 2010-11-11 | — | — | US | claimed |
| WO-2010127976-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | claimed |
| EP-2427456-B1 | ISOXAZOLE-PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-02-05 | — | — | EP | disclosed |
| EP-2427456-B1 | ISOXAZOLE-PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-02-05 | — | — | EP | disclosed |
| US-8415379-B2 | Pyridines | HOFFMANN-LA ROCHE INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415379-B2 | Pyridines | HOFFMANN-LA ROCHE INC. (US) | 2013-04-09 | — | — | US | disclosed |
| EP-2427456-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20100286132-A1 | PYRIDINES | ROCHE PALO ALTO LLC | 2010-11-11 | — | — | US | disclosed |
| US-20100286132-A1 | PYRIDINES | ROCHE PALO ALTO LLC | 2010-11-11 | — | — | US | disclosed |
| US-20100286132-A1 | PYRIDINES | ROCHE PALO ALTO LLC | 2010-11-11 | — | — | US | disclosed |
| WO-2010127976-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010127976-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286132-A1 | PYRIDINES | GABRA5, CHRNA5, GABRA1 | GABRA5 1/4885ITGA5 244/4885GABRA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.